VISION: 177Lu-PSMA-617 in Previously Treated Metastatic Castration-Resistant Prostate Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
In this phase III trial, addition of 177Lu-PSMA-617 to standard of care in men with previously treated PSMA-positive mCRPC prolonged OS and radiographic PFS vs standard of care alone.
Format: Microsoft PowerPoint (.ppt)
File Size: 459 KB
Released: June 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Exelixis
Merck Sharp & Dohme Corp.

Related Content

Clinical Care Options (CCO): Dr Heather Cheng answers audience questions from a live symposium on current and expanding role of PARP inhibitors in prostate cancer care

Heather H. Cheng, MD, PhD Released: April 26, 2022

Clinical Care Options (CCO): Expert analysis from Drs. Daniel Petrylak and Toni Choueiri on key data in genitourinary cancers from ASCO GU 2022

Toni K. Choueiri, MD Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 18, 2022 Expired: April 17, 2023

Video discussion by Drs. Wassim Abida, Heather Cheng, and Maha Hussain on optimal use of PARP inhibitors in prostate cancer, from Clinical Care Options (CCO)

Maha Hussain, MD, FACP, FASCO
Program Director
person default Wassim Abida, MD, PhD Heather H. Cheng, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: March 30, 2022 Expired: March 29, 2023

Clinical Care Options (CCO): Atish Choudhury, MD, PhD, provides insights into new and evolving treatment approaches in CSPC, including data from 2022 ASCO GU Cancers Symposium

Atish Choudhury, MD, PhD Released: March 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings